Skip to Content
Merck
CN
  • PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model.

PI3Kδ inhibition reduces TNF secretion and neuroinflammation in a mouse cerebral stroke model.

Nature communications (2014-03-15)
Pei Ching Low, Silvia Manzanero, Nika Mohannak, Vinod K Narayana, Tam H Nguyen, David Kvaskoff, Faith H Brennan, Marc J Ruitenberg, Mathias Gelderblom, Tim Magnus, Hyun Ah Kim, Brad R S Broughton, Christopher G Sobey, Bart Vanhaesebroeck, Jennifer L Stow, Thiruma V Arumugam, Frédéric A Meunier
ABSTRACT

Stroke is a major cause of death worldwide and the leading cause of permanent disability. Although reperfusion is currently used as treatment, the restoration of blood flow following ischaemia elicits a profound inflammatory response mediated by proinflammatory cytokines such as tumour necrosis factor (TNF), exacerbating tissue damage and worsening the outcomes for stroke patients. Phosphoinositide 3-kinase delta (PI3Kδ) controls intracellular TNF trafficking in macrophages and therefore represents a prospective target to limit neuroinflammation. Here we show that PI3Kδ inhibition confers protection in ischaemia/reperfusion models of stroke. In vitro, restoration of glucose supply following an episode of glucose deprivation potentiates TNF secretion from primary microglia-an effect that is sensitive to PI3Kδ inhibition. In vivo, transient middle cerebral artery occlusion and reperfusion in kinase-dead PI3Kδ (p110δ(D910A/D910A)) or wild-type mice pre- or post-treated with the PI3Kδ inhibitor CAL-101, leads to reduced TNF levels, decreased leukocyte infiltration, reduced infarct size and improved functional outcome. These data identify PI3Kδ as a potential therapeutic target in ischaemic stroke.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-MAP2 Antibody, clone AP20, clone AP20, Chemicon®, from mouse